What question did this study set out to answer?

To develop a low-cost, efficient diagnostic assay for sickle cell disease to improve access in resource-limited settings.

December 8, 2025BloodOpen Access

Antibody- and equipment-free, ultralow-cost point-of-care sickle cell disease diagnostic: An equitably accessible powerful assay

View Full Paper

Ask AI

Bookmark

Authors

Novel point-of-care assay achieves 100% sensitivity and 97% specificity in sickle cell diagnosis, indicating enhanced access to diagnostic services.

To develop a low-cost, efficient diagnostic assay for sickle cell disease to improve access in resource-limited settings.
Developed an antibody-independent, ultralow-cost point-of-care assay for sickle cell disease.
Tested the assay with a cohort of 166 individuals, comparing results with high-performance liquid chromatography.
Utilized smartphone photography for capturing morphological signatures of hemoglobin phenotypes.
Analyzed data using a Random Forest-based machine learning classifier.
Achieved 100% sensitivity and 97% specificity in distinguishing major hemoglobin phenotypes.
Test cost is less than 1 dollar and requires minimal sample manipulation and few salts.
Promises equitable access to sickle cell disease diagnostic services in low-resource regions.

Tite Minga Mikobi (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Novel point-of-care assay achieves 100% sensitivity and 97% specificity in sickle cell diagnosis, indicating enhanced access to diagnostic services.